The has been approved in Europe, Abbott's Tendyne, for valves too damaged for repair or patients too high risk for open surgery. The device is in U.S. clinical trials. (MedTech Dive)
Full 2-year results from the SURTAVI trial affirmed the 1-year Bayesian analysis' conclusion that in intermediate operative risk patients. (Journal of the American College of Cardiology, JACC)
Fully 40% of , had chronic cardiovascular or cerebrovascular disease in a report in The Lancet. See ľֱ's full coverage.
The , as mice switched from benefits to , researchers reported in Nature Metabolism. (Everyday Health)
The Centers for Medicare & Medicaid Services is opening up for comments on updating for bridge-to-transplant and destination therapy, specifically facility requirements.
Abbott's gained FDA Breakthrough Device designation, the company announced.
patients (5% of consecutive registry patients) was deemed appropriate in less than half of cases, suggesting "stricter adherence to international guidelines," Italian researchers reported in JACC: Cardiovascular Interventions.
It's an , for pigs, against a disease humans don't get. But could it rescue heparin supplies? (Farm Journal's Pork; ľֱ)
What to do when a left atrial appendage closure device embolizes or is malpositioned? A case series reports success of the . (JACC: Clinical Electrophysiology)
have been transplanted into a patient for the first time. (Japan Times)
Lymphoma drug vorinostat (Zolinza) in an animal model of heart failure with preserved ejection fraction. (Cardiovascular Business)
An "umbrella review" of turned up strong associations with risk for glimepiride (Amaryl) and rosiglitazone (Avandia) but reduced risk for glucagon-like peptide-1 receptor agonists as a class, sodium-glucose co-transporter-2 inhibitors as a class, and canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance), while pioglitazone (Actos) fell in both camps. (The Lancet Diabetes & Endocrinology)
could be due to its parylene coating, which a study showed resisted key bacteria better than bare or polyurethane coated titanium. (Journal of Cardiovascular Electrophysiology)
The FDA cleared atrial fibrillation and other cardiac conditions with its digital stethoscopes. (Mass Device)
A larger version of the (4-8 mm) gained pre-market approval for proximal popliteal and superficial femoral arteries, Intact Vascular announced.